Baicalin attenuates DDP (cisplatin) resistance in lung cancer by downregulating MARK2 and p-Akt

被引:55
|
作者
Xu, Zhiwei [1 ]
Mei, Ju [1 ]
Tan, Yan [2 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Cardiothorac Surg, Shanghai, Peoples R China
[2] Fudan Univ, Pudong Med Ctr, Shanghai Pudong Hosp, Dept Intens Care Unit, 2800 Gong Wei Rd, Shanghai 201399, Peoples R China
关键词
lung cancer; chemoresistance; baicalin; DDP; cisplatin; SCUTELLARIA-BAICALENSIS; BENZODIAZEPINE SITE; IN-VITRO; CELLS; CHEMOTHERAPY; EXPRESSION; OVARIAN; TARGET; INHIBITOR; APOPTOSIS;
D O I
10.3892/ijo.2016.3768
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
DDP (cisplatin) resistance in lung cancer has been widely reported. Baicalin is a flavone glycoside found in genus Scutellaria. However, the effects of baicalin on DDP resistance in lung cancer are unclear. The aim of present study was to investigate effects of combination of baicalin and DDP on proliferation and invasion of human lung cancer cells, and explore possible mechanisms. MTT assay was utilized to evaluate effects of baicalin and DDP on the proliferation of A549 and A549/DPP (DPP-resistant) human lung cancer cells. The probability sum method was used to determine effects of the drug combination. Transwell invasion assay was utilized to detect tumor cell invasion. The mRNA expression of MARK2 in A549 and A549/DPP cells was detected by qPCR. Protein expression of MARK2, p-Akt and Akt was detected by western blot analysis. Baicalin and DPP when used alone inhibited the proliferation of A549 and A549/DDP cells in a dose-dependent manner at 24 and 48 h. For A549 cells, baicalin (8 mu g/ml antagonized DDP (1, 2,4 and 8 mu g/ml) at 24 h. For A549/DDP cells, baicalin and DDP were additive when the concentration of DDP was 4 mu g/ml at 24 h. Effects of baicalin and DDP on proliferation inhibition were additive and synergistic when concentrations of DDP were 8 and 4 mu g/ml, respectively, at 48 h for both A549 and A549/DDP cells. When baicalin (8 mu g/ml) and DDP (4 mu g/ml) were combined, the inhibitory rate of tumor cell invasion increased markedly compared to DPP or baicalin alone groups in both A549 and A549/DDP cells. A549/DDP cells had significantly higher MARK2 mRNA levels and protein expression of MARK2 and p-Akt. Baicalin decreased MARK2 mRNA and protein expression of MARK2 and p-Akt in A549/DDP cells dose-dependently. In conclusion, baicalin and DDP were synergistic at inhibiting proliferation and invasion of human lung cancer cells at appropriate dosages and incubation time in the presence or absence of DDP resistance. The attenuation of DDP resistance was associated with downregulation of MARK2 and p-Akt.
引用
收藏
页码:93 / 100
页数:8
相关论文
共 50 条
  • [21] Cisplatin resistance in lung cancer is mediated by MACC1 expression through PI3K/AKT signaling pathway activation
    Zhang, Qiang
    Zhang, Bin
    Sun, Leina
    Yan, Qingna
    Zhang, Yu
    Zhang, Zhenfa
    Su, Yanjun
    Wang, Changli
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2018, 50 (08) : 748 - 756
  • [22] Orai3-Mediates Cisplatin-Resistance in Non-Small Cell Lung Cancer Cells by Enriching Cancer Stem Cell Population through PI3K/AKT Pathway
    Abou Daya, Hiba
    Kouba, Sana
    Ouled-Haddou, Hakim
    Benzerdjeb, Nazim
    Telliez, Marie-Sophie
    Dayen, Charles
    Sevestre, Henri
    Garcon, Loic
    Hague, Frederic
    Ouadid-Ahidouch, Halima
    CANCERS, 2021, 13 (10)
  • [23] miR-21 promotes growth, invasion and migration of lung cancer cells by AKT/P-AKT/cleaved-caspase 3/MMP-2/MMP-9 signaling pathway
    Li, Haiquan
    Zhao, Jie
    Jia, Xiaomin
    Zhang, Yanmin
    Du, Yongliang
    Li, Huiting
    Ma, Lei
    Huang, Jian'an
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2020, 13 (04): : 692 - 700
  • [24] Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation
    Belyanskaya, LL
    Hopkins-Donaldson, S
    Kurtz, S
    Simoes-Wüst, AP
    Yousefi, S
    Simon, HU
    Stahel, R
    Zangemeister-Wittke, U
    INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (05) : 755 - 763
  • [25] MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway
    Huang, Gang
    Lou, Tianzheng
    Pan, Jiongwei
    Ye, Zaiting
    Yin, Zhangyong
    Li, Lu
    Cheng, Wei
    Cao, Zhuo
    AGING-US, 2019, 11 (07): : 2138 - 2150
  • [26] MicroRNA-3196 is inhibited by H2AX phosphorylation and attenuates lung cancer cell apoptosis by downregulating PUMA
    Xu, Chengshan
    Zhang, Ling
    Duan, Lianning
    Lu, Chengrong
    ONCOTARGET, 2016, 7 (47) : 77764 - 77776
  • [27] Rhomboid domain-containing protein 1 promotes breast cancer progression by regulating the p-Akt and CDK2 levels
    Zhang, Xin
    Zhao, Yuechao
    Wang, Changjun
    Ju, Hongge
    Liu, Wenjie
    Zhang, Xiaohui
    Miao, Shiying
    Wang, Linfang
    Sun, Qiang
    Song, Wei
    CELL COMMUNICATION AND SIGNALING, 2018, 16
  • [28] Pentraxin 3 acts as a functional effector of Akt/NF-κB signaling to modulate the progression and cisplatin-resistance in non-small cell lung cancer
    Li, Yanguang
    Song, Xiang
    Niu, Jieting
    Ren, Mingming
    Tang, Guojie
    Sun, Zhen
    Kong, Fanyi
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2021, 701
  • [29] Depletion of UBE2C reduces ovarian cancer malignancy and reverses cisplatin resistance via downregulating CDK1
    Li, Jiajia
    Zhi, Xiuling
    Shen, Xiaoqing
    Chen, Chen
    Yuan, Lei
    Dong, Xuhui
    Zhu, Chenqi
    Yao, Liangqing
    Chen, Mo
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 523 (02) : 434 - 440
  • [30] Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer
    Pinhel, Isabel F.
    MacNeill, Fiona A.
    Hills, Margaret J.
    Salter, Janine
    Detre, Simone
    A'Hern, Roger
    Nerurkar, Ashutosh
    Osin, Peter
    Smith, Ian E.
    Dowsett, Mitch
    BREAST CANCER RESEARCH, 2010, 12 (05)